{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T04:53:28Z","timestamp":1764996808597,"version":"build-2065373602"},"reference-count":87,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2006,7,1]],"date-time":"2006-07-01T00:00:00Z","timestamp":1151712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,7,1]],"date-time":"2006-07-01T00:00:00Z","timestamp":1151712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surgonc.theclinics.com","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Oncology Clinics of North America"],"published-print":{"date-parts":[[2006,7]]},"DOI":"10.1016\/j.soc.2006.05.004","type":"journal-article","created":{"date-parts":[[2007,1,10]],"date-time":"2007-01-10T10:10:36Z","timestamp":1168423836000},"page":"511-533","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Treatment of Metastatic Disease in Patients with Neuroendocrine Tumors"],"prefix":"10.1016","volume":"15","author":[{"given":"John E.","family":"Niederhuber","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tito","family":"Fojo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.soc.2006.05.004_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/gut.2004.053314","article-title":"Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours","volume":"54","author":"Ramage","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.soc.2006.05.004_bib2","first-page":"2289","article-title":"Analysis of endoderm formation in the avian blastoma by use of qual-chic chimeras","volume":"38","author":"Fontaine","year":"1979","journal-title":"Fed Proc"},{"issue":"4","key":"10.1016\/j.soc.2006.05.004_bib3","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.bpg.2005.02.013","article-title":"Management of metastatic endocrine tumors","volume":"19","author":"Pl\u00f6ckinger","year":"2005","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.soc.2006.05.004_bib4","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1046\/j.1365-2168.2001.01644.x","article-title":"Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors","volume":"88","author":"Lebtahi","year":"2001","journal-title":"Br J Surg"},{"key":"10.1016\/j.soc.2006.05.004_bib5","first-page":"184","article-title":"Bone metastases in carcinoid tumors: clinical features, imaging characteristics, and markers of bone metabolism","volume":"44","author":"Meijer","year":"2003","journal-title":"J Nucl Med"},{"key":"10.1016\/j.soc.2006.05.004_bib6","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1097\/00006231-200208000-00006","article-title":"Evaluation of (111)IN-pentetreotide, (131)-MIBG and bone scintigraphy in the detection and clinical management of bone metastases in carcinoid disease","volume":"23","author":"Zuetenhorst","year":"2002","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.soc.2006.05.004_bib7","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1200\/JCO.1998.16.3.1040","article-title":"Bone metastases in patients with gastrinomas: a prospective study of bone scanning, somatostatin receptor scanning, and magnetic resonance image in their detection, frequency, location, and effect of their management","volume":"16","author":"Gibril","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.soc.2006.05.004_bib8","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1023\/B:NEON.0000014517.56866.bc","article-title":"Single brain metastases of carcinoid tumors","volume":"66","author":"Maiuri","year":"2004","journal-title":"J Neurooncol"},{"key":"10.1016\/j.soc.2006.05.004_bib9","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1536-1632(03)00038-6","article-title":"Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe (I)-Tyr (3)-Octreotide in comparison to [111In]-DTPAOC SPECT first results in patients with neuroendocrine tumors","volume":"5","author":"Kowalski","year":"2003","journal-title":"Mol Imaging Biol"},{"issue":"4","key":"10.1016\/j.soc.2006.05.004_bib10","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.bpg.2005.04.003","article-title":"Surgical treatment of neuroendocrine metastases","volume":"19","author":"Norton","year":"2005","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.soc.2006.05.004_bib11","first-page":"1147","article-title":"Cryosurgical ablation and radiofrequency ablation for unresectable hepatic malignant neoplasm","volume":"122","author":"Bilchick","year":"2000","journal-title":"Arch Surg"},{"key":"10.1016\/j.soc.2006.05.004_bib12","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/(SICI)1098-2388(199803)14:2<175::AID-SSU10>3.0.CO;2-2","article-title":"Cryotherapy for neuroendocrine liver metastases","volume":"14","author":"Seifert","year":"1998","journal-title":"Semin Surg Oncol"},{"key":"10.1016\/j.soc.2006.05.004_bib13","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0039-6060(97)90221-X","article-title":"Laparoscopic thermal ablation of hepatic neuroendocrine tumor metastases","volume":"122","author":"Siperstein","year":"1997","journal-title":"Surgery"},{"key":"10.1016\/j.soc.2006.05.004_bib14","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00268-001-0015-6","article-title":"Cryoablation, percutaneous alcohol injection, and radiofrequency ablation for treatment of neuroendocrine liver metastases","volume":"25","author":"Siperstein","year":"2001","journal-title":"World J Surg"},{"key":"10.1016\/j.soc.2006.05.004_bib15","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s00268-002-6629-5","article-title":"Laparoscopic radiofrequency ablation of neuroendocrine liver metastases","volume":"26","author":"Berber","year":"2002","journal-title":"World J Surg"},{"key":"10.1016\/j.soc.2006.05.004_bib16","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1007\/s00268-002-6663-3","article-title":"Radiofrequency tissue ablation using cooled tip for liver metastases of endocrine tumors","volume":"26","author":"Hellman","year":"2002","journal-title":"World J Surg"},{"key":"10.1016\/j.soc.2006.05.004_bib17","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1053\/sonc.2002.31677","article-title":"Percutaneous alcohol ablation for liver metastasis","volume":"29","author":"Giovanni","year":"2002","journal-title":"Semin Oncol"},{"key":"10.1016\/j.soc.2006.05.004_bib18","first-page":"260","article-title":"Ultrasound guided percutaneous ethanol injection in therapy of hepatic tumors and metastases","volume":"1","author":"Livraghi","year":"1993","journal-title":"Z Gastroenterol"},{"key":"10.1016\/j.soc.2006.05.004_bib19","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1677\/erc.0.0100463","article-title":"Ablative therapies for liver metastases of digestive endocrine tumours","volume":"10","author":"O'Toole","year":"2003","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.soc.2006.05.004_bib20","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/s002689900030","article-title":"Treatment of liver metastases of carcinoid tumors","volume":"20","author":"Ahlman","year":"1996","journal-title":"World J Surg"},{"key":"10.1016\/j.soc.2006.05.004_bib21","first-page":"1546","article-title":"Treatment of pancreatic-duodenal endocrine tumors","volume":"52","author":"O'Toole","year":"2002","journal-title":"La Revue du Paticien"},{"key":"10.1016\/j.soc.2006.05.004_bib22","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1148\/radiology.189.2.7692465","article-title":"Transcatheter chemoembolization of progressive carcinoid liver metastasis","volume":"189","author":"Therasse","year":"1993","journal-title":"Radiology"},{"issue":"4","key":"10.1016\/j.soc.2006.05.004_bib23","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.bpg.2005.02.012","article-title":"Biotherapy for metastatic endocrine tumors","volume":"19","author":"Shah","year":"2005","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"48","key":"10.1016\/j.soc.2006.05.004_bib24","doi-asserted-by":"crossref","first-page":"7676","DOI":"10.3748\/wjg.v11.i48.7676","article-title":"Liver transplantation for metastatic neuroendocrine tumor: a case report and review of the literature","volume":"11","author":"Blonski","year":"2005","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.soc.2006.05.004_bib25","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1046\/j.1365-2036.2003.01420.x","article-title":"Sandostatin LAR (long-acting octreotide acetate) for malignant carcinoid syndrome: a 3-year experience","volume":"17","author":"Garland","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.soc.2006.05.004_bib26","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/cncr.10195","article-title":"Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma","volume":"24","author":"Shojamanesh","year":"2002","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.soc.2006.05.004_bib27","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/(SICI)1097-0142(20000215)88:4<770::AID-CNCR6>3.0.CO;2-0","article-title":"Treatment of carcinoid syndrome. A prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability and tolerance","volume":"88","author":"O'Toole","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.soc.2006.05.004_bib28","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1006\/frne.1999.0183","article-title":"Somatostatin and its receptor family","volume":"20","author":"Patel","year":"1992","journal-title":"Front Neuroendocrinol"},{"key":"10.1016\/j.soc.2006.05.004_bib29","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1055\/s-2007-1019383","article-title":"Somatostatin half-life: a case report in one healthy volunteer and a three-month follow-up","volume":"13","author":"Bethge","year":"1981","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.soc.2006.05.004_bib30","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/0024-3205(82)90087-X","article-title":"SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action","volume":"31","author":"Briner","year":"1982","journal-title":"Life Sci"},{"issue":"8, Suppl 1","key":"10.1016\/j.soc.2006.05.004_bib31","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S0026-0495(96)90074-8","article-title":"Improved analogs and novel delivery systems for somatostatin octapeptides","volume":"45","author":"Moreau","year":"1996","journal-title":"Metabolism"},{"issue":"2 Pt 3","key":"10.1016\/j.soc.2006.05.004_bib32","article-title":"Regulation of cell proliferation by somatostatin","volume":"63","author":"Buscail","year":"2002","journal-title":"Annales d'Endocrinologie"},{"key":"10.1016\/j.soc.2006.05.004_bib33","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1177\/030089160308900201","article-title":"Current treatments of neuroendocrine tumors role of biotherapy and chemotherapy","volume":"89","author":"Della Torre","year":"2003","journal-title":"Tumori"},{"key":"10.1016\/j.soc.2006.05.004_bib34","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1385\/MO:19:1:35","article-title":"Treatment of malignant endocrine pancreatic tumors with a combination of alpha interferon and somatostatin analogs","volume":"19","author":"Fjallskog","year":"2002","journal-title":"Med Oncol"},{"key":"10.1016\/j.soc.2006.05.004_bib35","first-page":"1381","article-title":"Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors","volume":"94","author":"Frank","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.soc.2006.05.004_bib36","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/bjs.4149","article-title":"Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumors","volume":"90","author":"Kolby","year":"2003","journal-title":"Br J Surg"},{"key":"10.1016\/j.soc.2006.05.004_bib37","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1200\/JCO.2003.12.142","volume":"21","author":"Faiss","year":"2003","journal-title":"J Clin Oncol"},{"issue":"Supplement 4","key":"10.1016\/j.soc.2006.05.004_bib38","doi-asserted-by":"crossref","first-page":"iv293","DOI":"10.1093\/annonc\/mdh942","article-title":"Management of neuroendocrine tumors","volume":"15","author":"Oberg","year":"2004","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.soc.2006.05.004_bib39","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.bpg.2005.04.001","article-title":"Peptide receptor radionuclide therapy","volume":"19","author":"Teunissen","year":"2005","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.soc.2006.05.004_bib40","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00259-002-1050-8","article-title":"Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [(177)Lus-DOTA(0), Tyr(3)] octreotate","volume":"30","author":"Kwekkeboom","year":"2003","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.soc.2006.05.004_bib41","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1053\/snuc.2002.31027","article-title":"Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings","volume":"32","author":"De Jong","year":"2002","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.soc.2006.05.004_bib42","first-page":"1026","article-title":"Receptor-targeted radionuclide therapy using radiolabelled somatostatin analogues: tumour size versus curability","volume":"28","author":"De Jong","year":"2001","journal-title":"J Nucl Med"},{"key":"10.1016\/j.soc.2006.05.004_bib43","first-page":"1841","article-title":"Tumor response after [(90)Y-DOTA(0), Tyr(3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size","volume":"42","author":"De Jong","year":"2001","journal-title":"J Nucl Med"},{"key":"10.1016\/j.soc.2006.05.004_bib44","first-page":"13S","article-title":"Combination radionuclide therapy using 177Lu- and 90Y- labeled somatostatin analogs","volume":"46","author":"De Jong","year":"2005","journal-title":"J Nucl Med"},{"key":"10.1016\/j.soc.2006.05.004_bib45","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/jso.10062","article-title":"Regression of metastatic carcinoid tumors with octreotide therapy: two case reports and a review of the literature","volume":"79","author":"Leong","year":"2002","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.soc.2006.05.004_bib46","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1046\/j.1365-2265.2000.01126.x","article-title":"Complete histological regression of metastatic carcinoid tumor after treatment with octreotide","volume":"53","author":"Imtiaz","year":"2000","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.soc.2006.05.004_bib47","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1111\/j.1572-0241.2000.03210.x","article-title":"The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors","volume":"95","author":"Ducrux","year":"2000","journal-title":"Am J Gastroenterol"},{"issue":"Suppl 1","key":"10.1016\/j.soc.2006.05.004_bib48","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1159\/000080747","article-title":"Chemotherapy for Gastro-enteropancreatic endocrine tumours","volume":"80","author":"O'Toole","year":"2004","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.soc.2006.05.004_bib49","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1200\/JCO.1987.5.10.1502","article-title":"Karnofsky memorial lecture. An odyssey in the land of small tumors","volume":"5","author":"Moertel","year":"1987","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.soc.2006.05.004_bib50","doi-asserted-by":"crossref","first-page":"108","DOI":"10.7326\/0003-4819-79-1-108","article-title":"Pancreatic islet cell carcinoma. Results of therapy with streptozotocin in 52 patients","volume":"79","author":"Broder","year":"1973","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.soc.2006.05.004_bib51","first-page":"662","article-title":"Phase II trial of irinotecan in patients with advanced carcinoid tumor","volume":"21","author":"Baker","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.soc.2006.05.004_bib52","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/1097-0142(20010415)91:8<1543::AID-CNCR1163>3.0.CO;2-N","article-title":"A phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors","volume":"91","author":"Ansell","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.soc.2006.05.004_bib53","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJM198011203032101","article-title":"Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma","volume":"303","author":"Moertel","year":"1980","journal-title":"N Engl J Med"},{"key":"10.1016\/j.soc.2006.05.004_bib54","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1056\/NEJM199202203260804","article-title":"Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma","volume":"326","author":"Moertel","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.soc.2006.05.004_bib55","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.ejca.2003.09.035","article-title":"The doxorubicin-streptozotocin combinations for the treatment of advanced well-differentiated pancreatic endocrine carcinoma: a judicious option?","volume":"40","author":"Delaunoit","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.soc.2006.05.004_bib56","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.bpg.2005.06.002","article-title":"Endocrine tumors of the pancreas","volume":"19","author":"Oberg","year":"2005","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.soc.2006.05.004_bib57","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1002\/1097-0142(19900501)65:9<1883::AID-CNCR2820650902>3.0.CO;2-3","article-title":"Medical treatment and long term survival in a prospective study of 84 patients with endocrine pancreatic tumors","volume":"65","author":"Eriksson","year":"1990","journal-title":"Cancer"},{"key":"10.1016\/j.soc.2006.05.004_bib58","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1200\/JCO.1992.10.12.1914","article-title":"Phase II trial of chlorozotocin and fluorouracil in islet cell carcinoma: A Southwest Oncology Group study","volume":"10","author":"Bukowski","year":"1992","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.soc.2006.05.004_bib59","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.1200\/JCO.2004.04.024","article-title":"Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas","volume":"22","author":"Kouvaraki","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.soc.2006.05.004_bib60","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1161\/01.CIR.0000133187.74800.B9","article-title":"Cardiovascular complications of cancer therapy: Diagnosis, pathogenesis, and management","volume":"109","author":"Yeh","year":"2004","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.soc.2006.05.004_bib61","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1200\/JCO.2005.03.6046","article-title":"Phase II study of temzolomide and thalidomide in patients with metastatic neuroendocrine tumors","volume":"24","author":"Kulke","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.soc.2006.05.004_bib62","first-page":"5846","article-title":"Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazole[5, 1-d]-1,2,3,5-tatrazin-4(3H)-one (CCRG81045; M&B 23831), a novel drug with potential as an alternative to dacarbazine","volume":"47","author":"Stevens","year":"1987","journal-title":"Cancer Res"},{"key":"10.1016\/j.soc.2006.05.004_bib63","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/1097-0142(19910715)68:2<227::AID-CNCR2820680202>3.0.CO;2-I","article-title":"Treatment of neuroendocrine carcinomas with combined etopisode and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms","volume":"68","author":"Moertel","year":"1991","journal-title":"Cancer"},{"key":"10.1016\/j.soc.2006.05.004_bib64","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/1097-0142(20010901)92:5<1101::AID-CNCR1426>3.0.CO;2-V","article-title":"Treatment with cisplatin and etoposide in patients with neuroendocrine tumors","volume":"92","author":"Fjallskog","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.soc.2006.05.004_bib65","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/sj.bjc.6690325","article-title":"Treatment of poorly differentiated neuroendocrine tumors with etoposide and cisplatin","volume":"81","author":"Mitry","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1016\/j.soc.2006.05.004_bib66","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/jco.2004.22.90140.4124","article-title":"A phase II trial of imatinib in patients with advanced carcinoid tumour","volume":"22","author":"Carr","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.soc.2006.05.004_bib67","first-page":"1469","article-title":"Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors","volume":"9","author":"Fjallskog","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.soc.2006.05.004_bib68","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1200\/JCO.2005.02.2194","article-title":"Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer","volume":"24","author":"Faivre","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.soc.2006.05.004_bib69","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1002\/1097-0142(19930415)71:8<2624::AID-CNCR2820710830>3.0.CO;2-B","article-title":"Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors: a prospective phase II study in 24 patients","volume":"71","author":"Ruszniewski","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.soc.2006.05.004_bib70","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/1097-0142(19930715)72:2<375::AID-CNCR2820720211>3.0.CO;2-D","article-title":"Durable hepatic tumor regression after arterial chemoembolization-infusion in patients with islet cell carcinoma of the pancreas metastatic to the liver","volume":"72","author":"Mavligit","year":"1993","journal-title":"Cancer"},{"issue":"Suppl 3","key":"10.1016\/j.soc.2006.05.004_bib71","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1159\/000201208","article-title":"Hepatic arterial chemoembolization for metastatic neuroendocrine tumors","volume":"55","author":"Clouse","year":"1994","journal-title":"Digestion"},{"key":"10.1016\/j.soc.2006.05.004_bib72","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0002-9610(99)80210-4","article-title":"Treatment of metastatic carcinoid tumors using multimodality therapy of octreotide acetate, intra-arterial chemotherapy, and hepatic arterial chemoembolization","volume":"169","author":"Diaco","year":"1995","journal-title":"Am J Surg"},{"issue":"Suppl 1","key":"10.1016\/j.soc.2006.05.004_bib73","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1159\/000051860","article-title":"Hepatic arterial chemoembolization in the management of advanced digestive endocrine tumors","volume":"62","author":"Ruszniewski","year":"2000","journal-title":"Digestion"},{"key":"10.1016\/j.soc.2006.05.004_bib74","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s00330-002-1558-0","article-title":"Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors","volume":"13","author":"Roche","year":"2003","journal-title":"Eur Radiol"},{"key":"10.1016\/j.soc.2006.05.004_bib75","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1007\/s002590050476","article-title":"Yttrium-90 DOTATOC: first clinical results","volume":"26","author":"Otte","year":"1999","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.soc.2006.05.004_bib76","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1023\/A:1011160913619","article-title":"The clinical value of 99Y-DOTA]-dPhel-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study","volume":"12","author":"Waldherr","year":"2001","journal-title":"Annal of Oncology"},{"key":"10.1016\/j.soc.2006.05.004_bib77","first-page":"610","article-title":"Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC","volume":"43","author":"Waldherr","year":"2002","journal-title":"J Nucl Med"},{"key":"10.1016\/j.soc.2006.05.004_bib78","first-page":"S100","article-title":"Does tumor response depend on the number of treatment sessions at constant injected dose using 90Yttrium-DOTATOC in neuroendocrine tumors","volume":"29","author":"Waldherr","year":"2002","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.soc.2006.05.004_bib79","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00259-002-1023-y","article-title":"Receptor radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study","volume":"30","author":"Bodei","year":"2003","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl 2","key":"10.1016\/j.soc.2006.05.004_bib80","first-page":"S232","article-title":"Long-term follow-up of a phase I study of peptide receptor radionuclide therapy (PRRT) with (90Y-DOTA0,Tyr3) octreotide in patients with somatostatin receptor positive tumours","volume":"30","author":"Valkema","year":"2003","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.soc.2006.05.004_bib81","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1053\/snuc.2002.31565","article-title":"In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial","volume":"32","author":"Virgolini","year":"2002","journal-title":"Semin Nucl Med"},{"issue":"Suppl 2","key":"10.1016\/j.soc.2006.05.004_bib82","first-page":"S238","article-title":"Intravenous and intra-arterial peptide receptor radionuclide therapy (PRRT) using Y-90-DOTA-Tyr-octreotate (Y-90-DOTA-TATE) in patients with metastatic neuroendocrine tumors","volume":"31","author":"Baum","year":"2004","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.soc.2006.05.004_bib83","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1007\/s00761-004-0771-7","article-title":"Peptidrezeptorvermittelte Radiotherapie (PRRT) neuroenodriner Tumoren Klinischen Indikationen und Erfahrung mit 90Yttrium-markierten Somatostatinanaloga","volume":"10","author":"Baum","year":"2004","journal-title":"Der Onkologe"},{"issue":"Suppl 2","key":"10.1016\/j.soc.2006.05.004_bib84","first-page":"S231","article-title":"Treatment with Lu-177-DOTA-Tyr3-octreotate in patients with neuroendocrine tumors: interim results","volume":"30","author":"Kwekkeboom","year":"2003","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.soc.2006.05.004_bib85","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/00000421-199802000-00008","article-title":"Doxorubicin, streptozocin, and 5-fluorouracil chemotherapy for patients with metastatic islet-cell carcinoma","volume":"21","author":"Rivera","year":"1998","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.soc.2006.05.004_bib86","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1002\/(SICI)1097-0142(19990915)86:6<944::AID-CNCR8>3.0.CO;2-P","article-title":"Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma","volume":"86","author":"Cheng","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.soc.2006.05.004_bib87","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/(SICI)1097-0142(19980715)83:2<372::AID-CNCR23>3.0.CO;2-P","article-title":"5-Fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors","volume":"83","author":"Bajetta","year":"1998","journal-title":"Cancer"}],"container-title":["Surgical Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320706000214?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320706000214?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T11:52:09Z","timestamp":1760961129000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1055320706000214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7]]},"references-count":87,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["S1055320706000214"],"URL":"https:\/\/doi.org\/10.1016\/j.soc.2006.05.004","relation":{},"ISSN":["1055-3207"],"issn-type":[{"type":"print","value":"1055-3207"}],"subject":[],"published":{"date-parts":[[2006,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Metastatic Disease in Patients with Neuroendocrine Tumors","name":"articletitle","label":"Article Title"},{"value":"Surgical Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.soc.2006.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}